GlassScriptPhysician profile
Khawla M Abusamra
NPI 1972969657
$5,297.33
in general payments reported to CMS, 2019-2025
35 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $616 · 2024: $2,240 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,115 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,114.85 |
| Education | $182.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $667.70 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $416.05 | 2024-2025 | |
| Emd Serono, INC. | $395.79 | 2023-2025 | Mavenclad, Mavenclad |
| Harmony Biosciences LLC | $394.51 | 2024-2025 | |
| Ucb, INC. | $350.86 | 2023-2025 | Briviact, Rystiggo |
| Neurocrine Biosciences, INC. | $341.72 | 2024-2025 | Ingrezza |
| Celgene Corporation | $299.93 | 2023-2025 | Zeposia |
| Abbvie INC. | $285.78 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $267.54 | 2023-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Genentech USA, INC. | $213.76 | 2023-2025 | Ocrevus, Ocrevus Zunovo, Activase |
| Kyowa Kirin, INC. | $161.51 | 2023-2025 | Nourianz |
| Lilly USA, LLC | $152.73 | 2024-2025 | Emgality, Kisunla, Amyvid |
| Eisai INC. | $149.48 | 2024-2025 | |
| Lundbeck LLC | $126.22 | 2025 | Vyepti |
| Sumitomo Pharma America, INC. | $105.50 | 2023-2024 | Aptiom |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $102.88 | 2024-2025 | Uplizna |
| Biogen, INC. | $86.00 | 2024-2025 | Vumerity, Tysabri |
| Ani Pharmaceuticals, INC. | $81.03 | 2025 | Purified Cortrophin Gel |
| Sk Life Science, INC. | $70.65 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $68.54 | 2024-2025 | Nuplazid |
| Tg Therapeutics, INC. | $66.61 | 2024-2025 | |
| Genentech, INC. | $66.52 | 2025 | Ocrevus |
| Alexion Pharmaceuticals, INC. | $64.98 | 2023 | Ultomiris |
| Otsuka America Pharmaceutical, INC. | $53.41 | 2023-2024 | Nuedexta |
| Hospira, INC. | $37.05 | 2024 | |
| Ge Healthcare | $35.82 | 2024 | |
| Axsome Therapeutics, INC. | $35.50 | 2023-2025 | Symbravo, Sunosi |
| Ipsen Biopharmaceuticals, INC | $33.48 | 2025 | Dysport |
| Argenx US, INC. | $32.85 | 2025 | Vyvgart Hytrulo |
| Grifols USA, LLC | $27.20 | 2023 | Gamunex-C |
| Amylyx Pharmaceuticals, INC. | $24.13 | 2024 | Relyvrio |
| Amneal Pharmaceuticals LLC | $23.09 | 2024 | Rytary |
| Averitas Pharma INC. | $22.63 | 2025 | Qutenza |
| Mdd US Operations, LLC | $20.64 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.24 | 2025 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Khawla Abusamra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.